vs

Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and X3 Holdings Co., Ltd. (XTKG). Click either name above to swap in a different company.

X3 Holdings Co., Ltd. is the larger business by last-quarter revenue ($5.0M vs $3.9M, roughly 1.3× Opus Genetics, Inc.).

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

IRD vs XTKG — Head-to-Head

Bigger by revenue
XTKG
XTKG
1.3× larger
XTKG
$5.0M
$3.9M
IRD

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
IRD
IRD
XTKG
XTKG
Revenue
$3.9M
$5.0M
Net Profit
Gross Margin
Operating Margin
Net Margin
Revenue YoY
-10.2%
Net Profit YoY
53.0%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRD
IRD
XTKG
XTKG
Q4 25
$3.9M
Q3 25
$3.1M
Q2 25
$2.9M
$5.0M
Q1 25
$4.4M
Q4 24
$4.3M
Q3 24
$3.9M
Q2 24
$1.1M
$6.6M
Q1 24
$1.7M
Net Profit
IRD
IRD
XTKG
XTKG
Q4 25
Q3 25
$-17.5M
Q2 25
$-7.4M
Q1 25
$-8.2M
Q4 24
Q3 24
$-7.5M
Q2 24
$-7.8M
$-57.6M
Q1 24
$-7.1M
Gross Margin
IRD
IRD
XTKG
XTKG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
28.0%
Q1 24
Operating Margin
IRD
IRD
XTKG
XTKG
Q4 25
Q3 25
-269.9%
Q2 25
-309.0%
Q1 25
-227.2%
Q4 24
Q3 24
-207.1%
Q2 24
-748.9%
-219.1%
Q1 24
-450.5%
Net Margin
IRD
IRD
XTKG
XTKG
Q4 25
Q3 25
-566.9%
Q2 25
-257.5%
Q1 25
-187.5%
Q4 24
Q3 24
-194.6%
Q2 24
-698.3%
-874.1%
Q1 24
-415.3%
EPS (diluted)
IRD
IRD
XTKG
XTKG
Q4 25
Q3 25
$-0.25
Q2 25
$-0.12
Q1 25
$-0.24
Q4 24
Q3 24
$-0.29
Q2 24
$-0.30
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRD
IRD
XTKG
XTKG
Cash + ST InvestmentsLiquidity on hand
$45.1M
$2.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$15.3M
$42.6M
Total Assets
$50.2M
$71.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRD
IRD
XTKG
XTKG
Q4 25
$45.1M
Q3 25
$30.8M
Q2 25
$32.4M
$2.6M
Q1 25
$41.8M
Q4 24
$30.3M
Q3 24
$36.6M
Q2 24
$41.4M
$1.5M
Q1 24
$47.2M
Stockholders' Equity
IRD
IRD
XTKG
XTKG
Q4 25
$15.3M
Q3 25
$6.0M
Q2 25
$17.5M
$42.6M
Q1 25
$5.1M
Q4 24
$6.7M
Q3 24
$34.3M
Q2 24
$40.6M
$125.5M
Q1 24
$46.1M
Total Assets
IRD
IRD
XTKG
XTKG
Q4 25
$50.2M
Q3 25
$36.1M
Q2 25
$38.7M
$71.7M
Q1 25
$48.2M
Q4 24
$36.9M
Q3 24
$40.4M
Q2 24
$44.8M
$171.3M
Q1 24
$51.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRD
IRD
XTKG
XTKG
Operating Cash FlowLast quarter
$-35.3M
$-1.1M
Free Cash FlowOCF − Capex
$-1.7M
FCF MarginFCF / Revenue
-34.1%
Capex IntensityCapex / Revenue
12.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRD
IRD
XTKG
XTKG
Q4 25
$-35.3M
Q3 25
$-6.2M
Q2 25
$-10.3M
$-1.1M
Q1 25
$-9.0M
Q4 24
$-25.6M
Q3 24
$-5.1M
Q2 24
$-7.3M
$-7.0M
Q1 24
$-5.7M
Free Cash Flow
IRD
IRD
XTKG
XTKG
Q4 25
Q3 25
Q2 25
$-1.7M
Q1 25
Q4 24
Q3 24
Q2 24
$-7.0M
Q1 24
FCF Margin
IRD
IRD
XTKG
XTKG
Q4 25
Q3 25
Q2 25
-34.1%
Q1 25
Q4 24
Q3 24
Q2 24
-106.9%
Q1 24
Capex Intensity
IRD
IRD
XTKG
XTKG
Q4 25
Q3 25
Q2 25
12.1%
Q1 25
Q4 24
Q3 24
Q2 24
0.3%
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IRD
IRD

Segment breakdown not available.

XTKG
XTKG

Consulting and technical support services$2.4M48%
Other$1.5M30%
Application development services$884.5K18%
Subscription services$215.4K4%

Related Comparisons